Description: 3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; Cipterbin, an anti-HER2 monoclonal antibody for the treatment of HER2-positive metastatic breast cancer; TNF, pre-filled aqueous injection solution. It also offers YISAIPU, the receptor fusion tumor necrosis factor inhibitor; Mandi-minoxidil tincture, an OTC external medicine for treating hair loss; EPIAO and SEPO, an erythropoietin injection; SPARIN, an injectable low-molecular-weight heparin calcium. In addition, the company provides MN709 Minoxidil Foam and Nalfuraphine hydrochloride tablets. Further, it provides trading, project management and consultation, technology, sports, financial, investment advisory, as well as manufactures medical devices; and offers agricultural services. The company has collaboration agreements with companies, such as Toray. 3SBio Inc. was founded in 1993 and is headquartered in Shenyang, the People's Republic of China.
Home Page: www.3sbio.com
No. 3 A1, Road 10
Shenyang,
China
Phone:
86 24 2538 6000
Officers
| Name | Title |
|---|---|
| Dr. Jing Lou M.D., Ph.D. | Co-Founder, Executive Chairman, CEO & President |
| Dr. Dongmei Su | Senior VP & Executive Director |
| Mr. Xiang He | Chief Financial Officer |
| Ms. Siu Kuen Lai FCIS, FCS | Company Secretary |
| Zhao Xinyi | Executive of IR |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 6.734 |
|---|---|
| Trailing PE: | 8.1111 |
| Price-to-Book MRQ: | 0.927 |
| Price-to-Sales TTM: | 0.2131 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 5607 |